Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:STWD
NYSE:STWDMortgage REITs

A Look At Starwood Property Trust (STWD) Valuation After Leadership Move And Ongoing High Dividend Focus

The spotlight on Starwood Property Trust (STWD) has sharpened as investors weigh its high dividend yield against interest rate and real estate cycle risks, while Starwood Capital refreshes U.S. asset management leadership with John Gonnella’s appointment. See our latest analysis for Starwood Property Trust. Despite the latest leadership move at Starwood Capital, Starwood Property Trust’s share price has been relatively steady, with a 2.21% 1 day share price return and a 1.15% 90 day share...
OM:SF
OM:SFEntertainment

Stillfront Group (OM:SF) Reports SEK 2.4b FY Loss Testing Profit Turnaround Narrative

Stillfront Group (OM:SF) closed out FY 2025 with Q4 revenue of SEK 1.4b and a basic EPS loss of SEK 4.72, alongside trailing 12 month figures showing revenue of SEK 6.1b and a basic EPS loss of SEK 4.75. Over the past six reported quarters, revenue has moved from SEK 1.8b in Q4 2024 to SEK 1.4b in Q4 2025. Quarterly basic EPS has swung between a profit of SEK 0.11 in Q3 2025 and a loss of SEK 14.38 in Q4 2024, setting up a results season where investors are likely to focus heavily on how...
TSE:9706
TSE:9706Infrastructure

Japan Airport Terminal (TSE:9706) Margin Expansion Reinforces Bullish Narratives In Q3 2026 Earnings

Japan Airport Terminal (TSE:9706) has put up another solid quarter, with Q3 2026 revenue at ¥75,595 million and basic EPS of ¥95.22, backed by trailing twelve month revenue of ¥285,507 million and EPS of ¥333.51. The company has seen revenue move from ¥69,801 million in Q3 2025 to ¥75,595 million in Q3 2026, while quarterly EPS has shifted from ¥72.92 to ¥95.22 over the same period, alongside trailing net income of ¥30,953 million. With trailing net margin at 10.8% and higher than a year...
NYSE:EMR
NYSE:EMRElectrical

Emerson Electric (EMR) Q1 Margin Improvement Reinforces Bullish Earnings Quality Narrative

Emerson Electric (EMR) opened fiscal 2026 with Q1 revenue of US$4.3b and basic EPS of US$1.08, alongside net income from continuing operations of US$605m. This sets a clear benchmark for how the year is starting to shape up. The company has seen quarterly revenue move between US$4.2b and US$4.9b over the past year, while basic EPS ranged from about US$0.86 to US$1.12. This gives investors a consistent read on earnings power as they track the latest print. With trailing net margin at 12.7% and...
NYSE:AMCR
NYSE:AMCRPackaging

Amcor (AMCR) Margin Compression In Q2 Earnings Tests Bullish Growth Narratives

Amcor (AMCR) has just posted Q2 2026 results with revenue of US$5.4b and net income of US$177m, equal to EPS of US$0.38, putting a fresh marker down for how the packaging group is currently earning its margins. The company has seen quarterly revenue move from US$3.2b in Q2 2025 through US$5.1b in Q4 2025 to US$5.7b in Q1 2026 and now US$5.4b, while EPS has ranged from US$0.56 in Q2 2025 to a small loss in Q4 2025 before landing at US$0.57 in Q1 2026 and US$0.38 this quarter. This sets up a...
NYSE:CCI
NYSE:CCISpecialized REITs

Is Crown Castle (CCI) Offering Value After Multi Year Share Price Decline?

Wondering if Crown Castle is offering value at its current share price, or if it is a value trap? This article walks through what the numbers suggest without the hype. The stock last closed at US$86.11, with a 1.4% gain over the past week, a 2.6% decline over the last month, a 2.9% decline year to date, a 0.8% return over 1 year, a 29.2% decline over 3 years, and a 33.4% decline over 5 years. Recent attention on Crown Castle has been driven by ongoing interest in tower and infrastructure...
NYSE:DAVA
NYSE:DAVAIT

Endava (DAVA) Is Down 15.6% After Conservative Guidance Highlights Slower Growth And Cautious Demand – Has The Bull Case Changed?

In recent days, Endava reiterated its emphasis on complex digital transformation projects while issuing conservative guidance that reflects slower revenue growth and cautious enterprise demand. This shift in tone has prompted a more reserved stance from analysts, who are reassessing the company’s risk profile and longer-term growth narrative. With conservative guidance underscoring slower revenue growth, we’ll now examine how this development reshapes Endava’s broader investment narrative...
NYSE:SHO
NYSE:SHOHotel and Resort REITs

How Portfolio Pruning, Renovations, and Dividends At Sunstone Hotel Investors (SHO) Has Changed Its Investment Story

Over the past year, Sunstone Hotel Investors has benefited from a recovering lodging market, steady dividend growth, and active portfolio reshaping through asset sales and selective acquisitions in high barrier to entry locations. Management’s emphasis on ongoing renovations and asset repositioning to enhance competitive strength, supported by stable business and leisure travel demand, is increasingly central to the company’s long-term investment story. We’ll now examine how Sunstone Hotel...
TSX:TRP
TSX:TRPOil and Gas

Is It Too Late To Consider TC Energy (TSX:TRP) After Its Strong Multi‑Year Run?

If you are wondering whether TC Energy shares still offer value after their recent run, or if the price already reflects the story, this article walks through the key numbers so you can judge that for yourself. The stock last closed at C$81.02, with returns of 2.8% over 7 days, 6.3% over 30 days, 5.4% year to date, 26.1% over 1 year, 92.3% over 3 years and 120.0% over 5 years. These figures naturally raise questions about how much upside or downside may be left. Recent news around TC Energy...
NasdaqGS:ABCL
NasdaqGS:ABCLLife Sciences

Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions?

AbCellera Biologics recently highlighted its transition from a service-focused antibody discovery platform to a clinical-stage biotech, with proprietary candidates ABCL635 and ABCL575 now in Phase 1 trials and more than 100 partnered programs contributing potential royalties. This shift toward owning drug assets, alongside a broad royalty portfolio that includes 18 clinical programs, marks a meaningful change in how AbCellera may create and capture value within biopharma. We’ll now examine...
NasdaqGS:ASTE
NasdaqGS:ASTEMachinery

Assessing Astec Industries (ASTE) Valuation After Strong Recent Share Price Performance

Recent performance snapshot for Astec Industries (ASTE) Astec Industries (ASTE) has drawn fresh attention after a strong run over the past year, with the stock showing positive returns over the past month, past 3 months, and year to date. See our latest analysis for Astec Industries. The recent 7 day share price return of 14.29% and 30 day share price return of 17.73% build on a year to date share price return of 22.03%, while the 1 year total shareholder return of 63.86% contrasts with a...
NasdaqGS:PRAX
NasdaqGS:PRAXBiotechs

Is Praxis Precision Medicines (PRAX) Now Pricing In Recent Pipeline Progress And Volatile Share Gains

If you are looking at Praxis Precision Medicines and wondering whether the recent excitement is already in the price, you are not alone. The stock closed at US$303.34, with a 9.5% gain over the last 30 days, a 5.9% return year to date, a 243.8% return over 1 year, a 366.0% return over 3 years, and a 62.0% decline over 5 years. Recent company specific news has kept Praxis in focus for investors and added context to these share price moves. Headlines around its pipeline progress, regulatory...